
H Uri Saragovi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/901966/publications.pdf Version: 2024-02-01



H HRI SARACOVI

#	Article	IF	CITATIONS
1	Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease. Journal of Comparative Neurology, 2000, 427, 19-30.	0.9	225
2	Reduction of cortical TrkA but not p75NTR protein in early-stage Alzheimer's disease. Annals of Neurology, 2004, 56, 520-531.	2.8	181
3	Changes in retinal expression of neurotrophins and neurotrophin receptors induced by ocular hypertension. Journal of Neurobiology, 2004, 58, 341-354.	3.7	105
4	Chronic and Acute Models of Retinal Neurodegeneration TrkA Activity Are Neuroprotective whereas p75NTR Activity Is Neurotoxic through a Paracrine Mechanism. Journal of Biological Chemistry, 2010, 285, 39392-39400.	1.6	98
5	Inhibition of p75NTR in glia potentiates TrkA-mediated survival of injured retinal ganglion cells. Molecular and Cellular Neurosciences, 2009, 40, 410-420.	1.0	92
6	Optimal Nerve Growth Factor Trophic Signals Mediated by Synergy of TrkA and p75 Receptor-Specific Ligands. Journal of Neuroscience, 1997, 17, 6031-6037.	1.7	88
7	A Novel Biased Allosteric Compound Inhibitor of Parturition Selectively Impedes the Prostaglandin F2α-mediated Rho/ROCK Signaling Pathway. Journal of Biological Chemistry, 2010, 285, 25624-25636.	1.6	87
8	Long-Lasting Rescue of Age-Associated Deficits in Cognition and the CNS Cholinergic Phenotype by a Partial Agonist Peptidomimetic Ligand of TrkA. Journal of Neuroscience, 2004, 24, 8009-8018.	1.7	84
9	Melanoma-derived small extracellular vesicles induce lymphangiogenesis and metastasis through an NGFR-dependent mechanism. Nature Cancer, 2021, 2, 1387-1405.	5.7	83
10	A kinase-deficient TrkC receptor isoform activates Arf6–Rac1 signaling through the scaffold protein tamalin. Journal of Cell Biology, 2006, 173, 291-299.	2.3	82
11	p75 Co-receptors Regulate Ligand-dependent and Ligand-independent Trk Receptor Activation, in Part by Altering Trk Docking Subdomains. Journal of Biological Chemistry, 2001, 276, 31023-31029.	1.6	80
12	Novel Approaches for Targeted Cancer Therapy. Current Cancer Drug Targets, 2004, 4, 313-326.	0.8	80
13	A TrkA-selective, Fast Internalizing Nerve Growth Factor-Antibody Complex Induces Trophic but Not Neuritogenic Signals. Journal of Biological Chemistry, 1998, 273, 34933-34940.	1.6	78
14	An Agonistic TrkB mAb Causes Sustained TrkB Activation, Delays RGC Death, and Protects the Retinal Structure in Optic Nerve Axotomy and in Glaucoma. , 2010, 51, 4722.		78
15	p75 ^{NTR} and Its Ligand ProNGF Activate Paracrine Mechanisms Etiological to the Vascular, Inflammatory, and Neurodegenerative Pathologies of Diabetic Retinopathy. Journal of Neuroscience, 2016, 36, 8826-8841.	1.7	58
16	Neurotrophic rationale in glaucoma: A TrkA agonist, but not NGF or a p75 antagonist, protects retinal ganglion cellsin vivo. Developmental Neurobiology, 2007, 67, 884-894.	1.5	56
17	Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity. Oncogene, 2004, 23, 3613-3621.	2.6	53
18	Selective Small Molecule Peptidomimetic Ligands of TrkC and TrkA Receptors Afford Discrete or Complete Neurotrophic Activities. Chemistry and Biology, 2005, 12, 1015-1028.	6.2	53

#	Article	IF	CITATIONS
19	Modulation of p75NTR prevents diabetes- and proNGF-induced retinal inflammation and blood–retina barrier breakdown in mice and rats. Diabetologia, 2013, 56, 2329-2339.	2.9	51
20	Functional mimetics of neurotrophins and their receptors. Biochemical Society Transactions, 2006, 34, 612-617.	1.6	49
21	In Glaucoma the Upregulated Truncated TrkC.T1 Receptor Isoform in Glia Causes Increased TNF-α Production, Leading to Retinal Ganglion Cell Death. , 2010, 51, 6639.		49
22	Bivalent Peptidomimetic Ligands of TrkC Are Biased Agonists and Selectively Induce Neuritogenesis or Potentiate Neurotrophin-3 Trophic Signals. ACS Chemical Biology, 2009, 4, 769-781.	1.6	48
23	Angiotensin II Type I and Prostaglandin F2α Receptors Cooperatively Modulate Signaling in Vascular Smooth Muscle Cells. Journal of Biological Chemistry, 2015, 290, 3137-3148.	1.6	48
24	Focused ultrasound delivery of a selective TrkA agonist rescues cholinergic function in a mouse model of Alzheimer's disease. Science Advances, 2020, 6, eaax6646.	4.7	46
25	A Pro-Nerve Growth Factor (proNGF) and NGF Binding Protein, α ₂ -Macroglobulin, Differentially Regulates p75 and TrkA Receptors and Is Relevant to Neurodegeneration <i>Ex Vivo</i> and <i>In Vivo</i> . Molecular and Cellular Biology, 2015, 35, 3396-3408.	1.1	45
26	Synthetic CD4 exocyclics inhibit binding of human immunodeficiency virus type 1 envelope to CD4 and virus replication in T lymphocytes. Nature Biotechnology, 1997, 15, 150-154.	9.4	44
27	A Combinatorial Method for Solution-Phase Synthesis of Labeled Bivalent β-Turn Mimics. Journal of the American Chemical Society, 2008, 130, 556-565.	6.6	43
28	A Neurotrophic Rationale for the Therapy of Neurodegenerative Disorders. Current Alzheimer Research, 2009, 6, 419-423.	0.7	43
29	Ligand-Dependent TrkA Activity in Brain Differentially Affects Spatial Learning and Long-Term Memory. Molecular Pharmacology, 2011, 80, 498-508.	1.0	41
30	An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of dry eye. Experimental Eye Research, 2011, 93, 503-512.	1.2	40
31	α2-Macroglobulin Is a Mediator of Retinal Ganglion Cell Death in Glaucoma. Journal of Biological Chemistry, 2008, 283, 29156-29165.	1.6	39
32	BDNF, NT-3 and Trk receptor agonist monoclonal antibodies promote neuron survival, neurite extension, and synapse restoration in rat cochlea ex vivo models relevant for hidden hearing loss. PLoS ONE, 2019, 14, e0224022.	1,1	39
33	Self Recognition in the Ig Superfamily. Journal of Biological Chemistry, 2000, 275, 26935-26943.	1.6	39
34	Loops and Secondary Structure Mimetics: Development and Applications in Basic Science and Rational Drug Design. Nature Biotechnology, 1992, 10, 773-778.	9.4	38
35	Design and Solution Structure of Functional Peptide Mimetics of Nerve Growth Factor. Journal of Medicinal Chemistry, 2000, 43, 3530-3540.	2.9	37
36	Neurotrophin receptor agonists and antagonists as therapeutic agents: An evolving paradigm. Neurobiology of Disease, 2017, 97, 139-155.	2.1	37

#	Article	IF	CITATIONS
37	p75-Nerve Growth Factor as an Antiapoptotic Complex: Independence versus Cooperativity in Protection from Enediyne Chemotherapeutic Agents. Molecular Pharmacology, 2002, 61, 710-719.	1.0	35
38	Small Molecule Peptidomimetic Ligands of Neurotrophin Receptors, Identifying Binding Sites, Activation Sites and Regulatory Sites. Current Pharmaceutical Design, 2002, 8, 2201-2216.	0.9	35
39	Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses. Journal of Clinical Investigation, 2021, 131, .	3.9	35
40	Differential roles of Trk and p75 neurotrophin receptors in tumorigenesis and chemoresistance ex vivo and in vivo. Cancer Chemotherapy and Pharmacology, 2010, 65, 1047-1056.	1.1	34
41	Role of proNGF/p75 signaling in bladder dysfunction after spinal cord injury. Journal of Clinical Investigation, 2018, 128, 1772-1786.	3.9	34
42	Differential cross-regulation of TrkA and TrkC tyrosine kinase receptors with p75. Oncogene, 2003, 22, 5677-5685.	2.6	33
43	TrkA Receptor "Hot Spots―for Binding of NT-3 as a Heterologous Ligand. Journal of Biological Chemistry, 2007, 282, 16754-16763.	1.6	33
44	Small molecule and protein-based neurotrophic ligands: agonists and antagonists as therapeutic agents. Expert Opinion on Therapeutic Patents, 1999, 9, 737-751.	2.4	32
45	Rapid High-Yield Production of Functional SARS-CoV-2 Receptor Binding Domain by Viral and Non-Viral Transient Expression for Pre-Clinical Evaluation. Vaccines, 2020, 8, 654.	2.1	32
46	Solution Structure and Internal Motion of a Bioactive Peptide Derived from Nerve Growth Factor. Journal of Biological Chemistry, 1998, 273, 23652-23658.	1.6	31
47	Syntheses and Activities of New C10β-Turn Peptidomimetics. Journal of Organic Chemistry, 2004, 69, 701-713.	1.7	31
48	Cholesterol biosynthesis and the pro-apoptotic effects of the p75 nerve growth factor receptor in PC12 pheochromocytoma cells. Molecular Brain Research, 2005, 139, 225-234.	2.5	29
49	The Adhesion and Differentiation-inhibitory Activities of the Immunoglobulin Superfamily Member, Carcinoembryonic Antigen, Can Be Independently Blocked. Journal of Biological Chemistry, 2003, 278, 14632-14639.	1.6	28
50	The intracellular domain of p75NTR as a determinant of cellular reducing potential and response to oxidant stress. Aging Cell, 2005, 4, 187-196.	3.0	28
51	HER2-Mediated Internalization of a Targeted Prodrug Cytotoxic Conjugate Is Dependent on the Valency of the Targeting Ligand. DNA and Cell Biology, 2005, 24, 351-358.	0.9	28
52	Neuronal Injury External to the Retina Rapidly Activates Retinal Glia, Followed by Elevation of Markers for Cell Cycle Re-Entry and Death in Retinal Ganglion Cells. PLoS ONE, 2014, 9, e101349.	1.1	25
53	Allosteric Noncompetitive Small Molecule Selective Inhibitors of CD45 Tyrosine Phosphatase Suppress T-Cell Receptor Signals and Inflammation In Vivo. Molecular Pharmacology, 2014, 85, 553-563.	1.0	25
54	Longitudinal study of retinal degeneration in a rat using spectral domain optical coherence tomography. Optics Express, 2010, 18, 23435.	1.7	23

#	Article	IF	CITATIONS
55	p75NTR antagonists attenuate photoreceptor cell loss in murine models of retinitis pigmentosa. Cell Death and Disease, 2017, 8, e2922-e2922.	2.7	23
56	P75 neurotrophin receptor regulates expression of neural cell adhesion molecule 1. Neurobiology of Disease, 2005, 20, 969-985.	2.1	22
57	During Glaucoma, α2-Macroglobulin Accumulates in Aqueous Humor and Binds to Nerve Growth Factor, Neutralizing Neuroprotection. , 2011, 52, 5260.		22
58	Neuroprotection: Pro-survival and Anti-neurotoxic Mechanisms as Therapeutic Strategies in Neurodegeneration. Frontiers in Cellular Neuroscience, 2019, 13, 231.	1.8	20
59	Vaccination with Tumor-Ganglioside Glycomimetics Activates a Selective Immunity that Affords Cancer Therapy. Cell Chemical Biology, 2019, 26, 1013-1026.e4.	2.5	20
60	Progression of age-associated cognitive impairment correlates with quantitative and qualitative loss of TrkA receptor protein in nucleus basalis and cortex. Journal of Neurochemistry, 2005, 95, 1472-1480.	2.1	19
61	A peptidomimetic of NT-3 acts as a TrkC antagonist. Peptides, 2009, 30, 1833-1839.	1.2	19
62	Nerve growth factor stimulation of ERK1/2 phosphorylation requires both p75NTR and α9β1 integrin and confers myoprotection towards ischemia in C2C12 skeletal muscle cell model. Cellular Signalling, 2012, 24, 2378-2388.	1.7	19
63	Ligands Binding to Cell Surface Ganglioside GD2 Cause Src-Dependent Activation of N-Methyl-D-Aspartate Receptor Signaling and Changes in Cellular Morphology. PLoS ONE, 2015, 10, e0134255.	1.1	19
64	Bivalent Diketopiperazine-Based Tropomysin Receptor Kinase C (TrkC) Antagonists. Journal of Medicinal Chemistry, 2010, 53, 5044-5048.	2.9	18
65	Raft-Dependent Endocytosis of Autocrine Motility Factor/Phosphoglucose Isomerase: A Potential Drug Delivery Route for Tumor Cells. PLoS ONE, 2008, 3, e3597.	1.1	18
66	Ultrasound delivery of a TrkA agonist confers neuroprotection to Alzheimer-associated pathologies. Brain, 2022, 145, 2806-2822.	3.7	18
67	A Receptor That Subserves Reovirus Binding Can Inhibit Lymphocyte Proliferation Triggered by Mitogenic Signals. DNA and Cell Biology, 1995, 14, 653-664.	0.9	17
68	Aiming for the Sweet Spot: Glyco-Immune Checkpoints and γδT Cells in Targeted Immunotherapy. Frontiers in Immunology, 2020, 11, 564499.	2.2	16
69	A ligand of the p65/p95 receptor suppresses perforant path kindling, kindling-induced mossy fiber sprouting, and hilar area changes in adult rats. Neuroscience, 2003, 119, 1147-1156.	1.1	15
70	Inhibition of CD45 Phosphatase Activity Induces Cell Cycle Arrest and Apoptosis of CD45+ Lymphoid Tumors Ex Vivo and In Vivo. Molecular Pharmacology, 2018, 93, 575-580.	1.0	15
71	Gangliosides: therapeutic agents or therapeutic targets?. Expert Opinion on Therapeutic Patents, 2002, 12, 1215-1223.	2.4	14
72	Selective Formation of Homo- and Heterobivalent Peptidomimetics. Journal of Medicinal Chemistry, 2003, 46, 3565-3567.	2.9	14

#	Article	lF	CITATIONS
73	Differential actions of nerve growth factor receptors TrkA and p75NTR in a rat model of epileptogenesis. Molecular and Cellular Neurosciences, 2005, 29, 162-172.	1.0	14
74	A monovalent agonist of TrkA tyrosine kinase receptors can be converted into a bivalent antagonist. Biochimica Et Biophysica Acta - General Subjects, 2010, 1800, 1018-1026.	1.1	14
75	UNG-1 and APN-1 are the major enzymes to efficiently repair 5-hydroxymethyluracil DNA lesions in C. elegans. Scientific Reports, 2018, 8, 6860.	1.6	14
76	The Paradoxical Signals of Two TrkC Receptor Isoforms Supports a Rationale for Novel Therapeutic Strategies in ALS. PLoS ONE, 2016, 11, e0162307.	1.1	14
77	Effective chimeric antigen receptor T cells against SARS-CoV-2. IScience, 2021, 24, 103295.	1.9	14
78	Preparation and Characterization of New Anti-PSMA Monoclonal Antibodies with Potential Clinical Use. Hybridoma, 2007, 26, 363-372.	0.5	13
79	An agonistic mAb directed to the TrkC receptor juxtamembrane region defines a trophic hot spot and interactions with p75 coreceptors. Developmental Neurobiology, 2010, 70, 150-164.	1.5	13
80	Combinatorial Assembly of Small Molecules into Bivalent Antagonists of TrkC or TrkA Receptors. PLoS ONE, 2014, 9, e89617.	1.1	12
81	Small-Molecule Ligands of GD2 Ganglioside, Designed from NMR Studies, Exhibit Induced-Fit Binding and Bioactivity. Chemistry and Biology, 2010, 17, 183-194.	6.2	11
82	The route of administration influences the therapeutic index of an anti-proNGF neutralizing mAb for experimental treatment of Diabetic Retinopathy. PLoS ONE, 2018, 13, e0199079.	1.1	11
83	Antagonism of proNGF or its receptor p75NTR reverses remodelling and improves bladder function in a mouse model of diabetic voiding dysfunction. Diabetologia, 2020, 63, 1932-1946.	2.9	11
84	Subconjunctival Delivery of p75 ^{NTR} Antagonists Reduces the Inflammatory, Vascular, and Neurodegenerative Pathologies of Diabetic Retinopathy. , 2017, 58, 2852.		10
85	A p65/p95 Neural Surface Receptor is Expressed at the S-G2Phase of the Cell Cycle and Defines Distinct Populations. European Journal of Neuroscience, 1996, 8, 273-281.	1.2	9
86	A G1Cell Cycle Arrest Induced by Ligands of the Reovirus Type 3 Receptor Is Secondary to Inactivation of p21ras and Mitogen-Activated Protein Kinase. DNA and Cell Biology, 1999, 18, 763-770.	0.9	9
87	In retinitis pigmentosa TrkC.T1-dependent vectorial Erk activity upregulates glial TNF-α, causing selective neuronal death. Cell Death and Disease, 2017, 8, 3222.	2.7	9
88	Small-molecule agonists of the RET receptor tyrosine kinase activate biased trophic signals that are influenced by the presence of GFRa1 co-receptors. Journal of Biological Chemistry, 2020, 295, 6532-6542.	1.6	9
89	Neurotrophins. , 2013, , 1639-1646.		7
90	Pharmacological interrogation of TrkA-mediated mechanisms in hippocampal-dependent memory consolidation. PLoS ONE, 2019, 14, e0218036.	1.1	7

#	Article	IF	CITATIONS
91	Constrained peptides and mimetics as probes of protein secondary structure. ImmunoMethods, 1992, 1, 5-9.	0.8	6
92	Synthesis and evaluation of novel dipeptidyl benzoyloxymethyl ketones as caspase inhibitors. Biochemical and Biophysical Research Communications, 2005, 336, 397-400.	1.0	6
93	Small-Molecule Ligands that Bind the RET Receptor Activate Neuroprotective Signals Independent of but Modulated by Coreceptor GFRα1. Molecular Pharmacology, 2020, 98, 1-12.	1.0	6
94	Signaling pathways mediating a selective induction of nitric oxide synthase II by tumor necrosis factor alpha in nerve growth factor-responsive cells. Journal of Neuroinflammation, 2005, 2, 19.	3.1	5
95	Therapeutic Neuroprotection by an Engineered Neurotrophin that Selectively Activates Tropomyosin Receptor Kinase (Trk) Family Neurotrophin Receptors but Not the p75 Neurotrophin Receptor. Molecular Pharmacology, 2021, 100, 491-501.	1.0	4
96	Rational Design of Peptide Ligands Against a Glycolipid by NMR Studies. Methods in Molecular Biology, 2012, 928, 39-52.	0.4	3
97	The Neurotrophins. , 2006, , 1407-1413.		2
98	Alternative Splicing of a Receptor Intracellular Domain Yields Different Ectodomain Conformations, Enabling Isoform-Selective Functional Ligands. IScience, 2020, 23, 101447.	1.9	2
99	Modulation of diabetic kidney disease markers by an antagonist of p75NTR in streptozotocin-treated mice. Gene, 2022, 838, 146729.	1.0	2
100	Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease. , 0, .		1